This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Patients with PAD had a ~35% increased risk of major cardiovascular events, but both liraglutide and semaglutide showed beneficial effects.
Why it matters
Understanding the cardiovascular benefits of these medications can help improve treatment strategies for diabetic patients at high risk of heart disease.
How the study worked
The study analyzed data from the LEADER and SUSTAIN 6 trials, comparing liraglutide and semaglutide to placebo in patients with type 2 diabetes and high cardiovascular risk.
What this study cannot tell us
The study's findings are based on trial data, which may not fully represent real-world scenarios.
Read the original research
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Diabetes, obesity & metabolism, 24(7), 1288-1299
Citation
Verma, Subodh; Al-Omran, Mohammed; Leiter, Lawrence A; Mazer, C David; Rasmussen, Søren; Saevereid, Hans A; Sejersten Ripa, Maria; Bonaca, Marc P. (2022). Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.. Diabetes, obesity & metabolism, 24(7), 1288-1299. https://doi.org/10.1111/dom.14700